In a report published Thursday, Morgan Stanley analyst Andrew Schenker initiated coverage on Centene Corp. CNC with an Equal-Weight rating.
In the report, Morgan Stanley noted, “While the Medicaid expansion, non-reform pipeline, and dual eligible opportunity will drive meaningful top-line growth we believe that much of this is priced into the stock. Lack of new RFPs in the near term could pressure the multiple as earnings growth normalizes over the next few years. Better/worse than expected execution on new contracts and Medicaid lives drives upside/downside.”
Centene Corp. closed on Wednesday at $57.33.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in